GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours

Virchows Archiv

Volumn 462, Issue 2, 2013, Pages 203-209

  Ramani, Pramila ^a,b   Headford, Alison ^a   May, Margaret T ^b  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

GLUT1; Hypoxia; Immunohistochemistry; Neuroblastoma

Indexed keywords

GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; DNA; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; SLC2A1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BLASTOMA; BRAIN TUMOR; CHILD; CLINICAL ARTICLE; EVENT FREE SURVIVAL; GENE; GENE AMPLIFICATION; HIGH RISK PATIENT; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; LOW RISK POPULATION; MYCN GENE; NERVE CELL; NEUROBLAST; NEUROBLASTIC TUMOR; NEUROBLASTOMA; NODULAR GANGLIONEUROBLASTOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADOLESCENT; GENETICS; METABOLISM; MITOSIS; MORTALITY; NECROSIS; NEWBORN; NUCLEIC ACID AMPLIFICATION; PATHOLOGY; PERIPHERAL NERVE TUMOR; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DNA, NEOPLASM; GANGLIONEUROBLASTOMA; GLUCOSE TRANSPORTER TYPE 1; HUMANS; INFANT; INFANT, NEWBORN; MITOSIS; NECROSIS; NEUROBLASTOMA; NUCLEAR PROTEINS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; ONCOGENE PROTEINS; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84877133364     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1370-4     Document Type: Article

References (26)

1. Maris JM, Hogarty MD, Bagatell R et al (2007) Neuroblastoma. Lancet 369:2106-2120
2. Brodeur GM, Pritchard J, Berthold F et al (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477
3. Cohn SL, Pearson AD, London WB et al (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27:289-297
4. Peuchmaur M, d'Amore ES, Joshi VV et al (2003) Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 98:2274-2281
5. Shimada H, Ambros IM, Dehner LP et al (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364-372
6. Shimada H, Umehara S, Monobe Y et al (2001) International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 92:2451-2461
7. Janoueix-Lerosey I, Schleiermacher G, Delattre O (2010) Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 29:1566-1579
8. Monclair T, Brodeur GM, Ambros PF et al (2009) The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 27:298-303
9. Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33:207-214
10. Dungwa JV, Hunt LP, Ramani P (2012) HIF-1alpha up-regulation is associated with adverse clinicopathological and biological factors in neuroblastomas. Histopathology 61:417-427
11. Dungwa JV, Hunt LP, Ramani P (2012) Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas. Hum Pathol 43:1651-1660
12. Hu CJ, Wang LY, Chodosh LA et al (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23:9361-9374
13. Amann T, Hellerbrand C (2009) GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 13:1411-1427
14. Ayala FR, Rocha RM, Carvalho KC et al (2010) GLUT1 and GLUT3 as potential prognostic markers for Oral Squamous Cell Carcinoma. Molecules 15:2374-2387
15. Younes M, Brown RW, Stephenson M et al (1997) Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80:1046-1051
16. Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225-239
17. Mendez LE, Manci N, Cantuaria G et al (2002) Expression of glucose transporter-1 in cervical cancer and its precursors. Gynecol Oncol 86:138-143
18. Porporato PE, Dhup S, Dadhich RK et al (2011) Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2:49. doi: 10.3389/fphar.2011.00049
19. Jogi A, Vallon-Christersson J, Holmquist L et al (2004) Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth, survival, and aggressive behavior. Exp Cell Res 295:469-487
20. Qing G, Skuli N, Mayes PA et al (2010) Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1 {alpha}. Cancer Res 70:10351-10361
21. Matsushita K, Uchida K, Saigusa S et al (2012) Glycolysis inhibitors as a potential therapeutic option to treat aggressive neuroblastoma expressing GLUT1. J Pediatr Surg 47:1323-1330
22. Jubb AM, Buffa FM, Harris AL (2010) Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med 14:18-29
23. Bardos JI, Ashcroft M (2005) Negative and positive regulation of HIF-1: a complex network. Biochim Biophys Acta 1755:107-120
24. Ljungkvist AS, Bussink J, Rijken PF et al (2000) Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys 48:1529-1538
25. Brand K (1997) Aerobic glycolysis by proliferating cells: protection against oxidative stress at the expense of energy yield. J Bioenerg Biomembr 29:355-364
26. Ito S, Fukusato T, Nemoto T et al (2002) Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. J Natl Cancer Inst 94:1080-1091